Abstract
Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be useful for quantitatively detecting MOP.
Keywords: Knockout mice, μ opioid receptor, quantification, Western blot analysis, alcohol-dependent, chronic cocaine, downregulates MOP mRNA, immunohistochemistry, MOP binding, mRNA levels, MOP proteins
Current Neuropharmacology
Title: Quantitative Detection of μ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice
Volume: 9 Issue: 1
Author(s): Shinya Kasai, Hideko Yamamoto, Etsuko Kamegaya, George R. Uhl, Ichiro Sora, Masahiko Watanabe and Kazutaka Ikeda
Affiliation:
Keywords: Knockout mice, μ opioid receptor, quantification, Western blot analysis, alcohol-dependent, chronic cocaine, downregulates MOP mRNA, immunohistochemistry, MOP binding, mRNA levels, MOP proteins
Abstract: Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be useful for quantitatively detecting MOP.
Export Options
About this article
Cite this article as:
Kasai Shinya, Yamamoto Hideko, Kamegaya Etsuko, R. Uhl George, Sora Ichiro, Watanabe Masahiko and Ikeda Kazutaka, Quantitative Detection of μ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795016921
DOI https://dx.doi.org/10.2174/157015911795016921 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Commentary (Research Highlights: Linking Productive Autophagy to Neuroprotection: Potential Implications for Anti-Ischemic Therapy)
CNS & Neurological Disorders - Drug Targets Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders
Current Alzheimer Research Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets Non-Covalent Interactions with Aromatic Rings: Current Understanding and Implications for Rational Drug Design
Current Pharmaceutical Design Meet Our Editor
Current Metabolomics Novel Therapeutic Targets for the Treatment of Depression
Current Medicinal Chemistry - Central Nervous System Agents Costing Human Rights and Community Support Interventions as a Part of Universal Access to HIV Treatment and Care in a Southern African Setting
Current HIV Research Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Complement Receptors in HIV Infection
Current Molecular Medicine Tualang Honey and its Methanolic Fraction Improve LPS-induced Learning and Memory Impairment in Male Rats: Comparison with Memantine
Current Nutrition & Food Science Atomic Force Microscopy: The Characterisation of Amyloid Protein Structure in Pathology
Current Topics in Medicinal Chemistry Peroxisome Proliferator-Activated Receptor Agonists as Potential Therapeutic Agents in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry The Cholinergic System: An Emerging Drug Target for Schizophrenia
Current Pharmaceutical Design Orofacial Pain and Mastication in Dementia
Current Alzheimer Research Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Genetic Analysis of CYP2D6 Polymorphism in Indian Populations and its Pharmacogenetic Implications
Current Pharmacogenomics and Personalized Medicine ERRATUM 1
Current Neuropharmacology